We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Illumina (ILMN - Free Report) closed the most recent trading day at $271.71, moving -0.17% from the previous trading session. This move lagged the S&P 500's daily gain of 1.08%. Meanwhile, the Dow gained 0.91%, and the Nasdaq, a tech-heavy index, added 1.31%.
Heading into today, shares of the genetic testing tools company had lost 6.77% over the past month, lagging the Medical sector's loss of 1.27% and the S&P 500's loss of 0.68% in that time.
ILMN will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $1.41, down 7.24% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $870.91 million, up 2.1% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.04 per share and revenue of $3.52 billion, which would represent changes of +5.59% and +5.64%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for ILMN. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ILMN is currently a Zacks Rank #4 (Sell).
Digging into valuation, ILMN currently has a Forward P/E ratio of 45.04. This valuation marks a premium compared to its industry's average Forward P/E of 26.54.
Meanwhile, ILMN's PEG ratio is currently 2.54. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.73 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 95, which puts it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know
Illumina (ILMN - Free Report) closed the most recent trading day at $271.71, moving -0.17% from the previous trading session. This move lagged the S&P 500's daily gain of 1.08%. Meanwhile, the Dow gained 0.91%, and the Nasdaq, a tech-heavy index, added 1.31%.
Heading into today, shares of the genetic testing tools company had lost 6.77% over the past month, lagging the Medical sector's loss of 1.27% and the S&P 500's loss of 0.68% in that time.
ILMN will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $1.41, down 7.24% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $870.91 million, up 2.1% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.04 per share and revenue of $3.52 billion, which would represent changes of +5.59% and +5.64%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for ILMN. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ILMN is currently a Zacks Rank #4 (Sell).
Digging into valuation, ILMN currently has a Forward P/E ratio of 45.04. This valuation marks a premium compared to its industry's average Forward P/E of 26.54.
Meanwhile, ILMN's PEG ratio is currently 2.54. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.73 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 95, which puts it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.